IRVINE, Calif. and AMSTERDAM , Feb. 18, 2020 /PRNewswire/ -- Agendia, Inc. , a world leader in precision oncology for breast cancer, announced today that BMC Cancer published results from the IMPACt trial. The study measured changes in both treatment decisions and physician confidence when using the MammaPrint® and BluePrint® assays to support medical management for patie
February 18, 2020
· 4 min read